Xencor Inc

XNCR · NASDAQ

Pharmaceutical Preparation Manufacturing

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action.

ESG Scores

Overall ESG

5.7

Environmental

4.7

Social

3.4

Governance

7.2

Gender Diversity

Female Directors0.375%

Female Executives0.043478260869565216%

Women in Workforce0.563%

CEO GenderMale

Market Data

Price$13.06+0.61 (+4.90%)

Market Cap$942M

P/E Ratio—

EPS$—

52W High$18.69

52W Low$6.92

Beta1.02